BioCryst Pharmaceuticals vs Krystal Biotech
BCRX and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and KRYS compare
Krystal Biotech is the larger company, worth 4.5 times as much as BioCryst Pharmaceuticals ($9.8B against $2.2B).
BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 22.6% for Krystal Biotech).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with −40.9% at BioCryst Pharmaceuticals.
Krystal Biotech scores higher on the StockData Score (10 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | KRYS |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $9.8B |
| Share price | $8.47 | $332.29 |
| Change, 1 year | 15.9% | 79.6% |
| Change, 5 years | −31.7% | 548% |
| Beta (5Y) | 0.80 | 0.84 |
| Employees | 435 | 295 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 41.6× |
| P/S | 2.3× (better) | 22.3× |
| P/B | – | 7.2× |
| EV/EBITDA | – | 45.5× |
| P/FCF | 5.8× (better) | 38.2× |
| FCF yield | 17.3% (better) | 2.6% |
| Fair value | – | $157.63 |
| Margin of safety | – | −111% |
| Growth | ||
| Revenue growth (TTM) | 68.7% (better) | 22.6% |
| Revenue growth, 5Y average | 118% | – |
| Net income growth (TTM) | – | 64.6% |
| EPS growth (TTM) | – | 62.2% |
| Profitability | ||
| Gross margin | 97.8% | – |
| Operating margin | −33.3% | 44.9% (better) |
| Net margin | −40.9% | 54.8% (better) |
| FCF margin | 39.7% | 58.5% (better) |
| Return on equity | – | 20.1% |
| Return on invested capital | – | 45.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.2× | – |
| Current ratio | 2.32 | 8.32 (better) |
| Altman Z-score | −3.68 | 43.30 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 102% |
| Held by insiders | 1.9% | 17.2% |
| Insider net buying, 12 months | −$4.1M (better) | −$105M |
| Short interest, % of float | 11.0% | 14.2% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.